Advertisement

Topics

Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting

13:28 EDT 17 May 2018 | Cancer Networks

Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

Original Article: Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting

NEXT ARTICLE

More From BioPortfolio on "Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...